Medtronic 8-K: Operations, Personnel Changes, Financials
Ticker: MDT · Form: 8-K · Filed: Aug 19, 2025 · CIK: 1613103
| Field | Detail |
|---|---|
| Company | Medtronic PLC (MDT) |
| Form Type | 8-K |
| Filed Date | Aug 19, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: operations, personnel, financials
Related Tickers: MDT
TL;DR
Medtronic dropped an 8-K detailing financials, exec changes, and exhibits as of Aug 18, 2025.
AI Summary
Medtronic plc filed an 8-K on August 19, 2025, reporting on its results of operations and financial condition as of August 18, 2025. The filing also disclosed the departure of directors or certain officers, the election of directors, and the appointment of certain officers, along with details on compensatory arrangements. Additionally, it included financial statements and exhibits.
Why It Matters
This filing provides crucial updates on Medtronic's financial health and leadership, impacting investor confidence and strategic direction.
Risk Assessment
Risk Level: low — This is a routine 8-K filing reporting on standard corporate events and financial information.
Key Players & Entities
- Medtronic plc (company) — Filer of the 8-K
- 20250818 (date) — Period of report and date as of change
- 20250819 (date) — Filing date
FAQ
What specific financial results were reported by Medtronic as of August 18, 2025?
The filing indicates reporting on 'Results of Operations and Financial Condition' as of August 18, 2025, but the specific financial figures are not detailed in the provided text.
Were there any changes in Medtronic's board of directors or executive officers?
Yes, the filing explicitly mentions 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers' as an item of information.
What is the filing date of this 8-K report?
The filing date is August 19, 2025.
What is Medtronic's Standard Industrial Classification (SIC) code?
Medtronic's SIC code is 3845, categorized under ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS.
Does the filing include information on compensatory arrangements for officers?
Yes, the filing lists 'Compensatory Arrangements of Certain Officers' as an item of information.
Filing Stats: 1,021 words · 4 min read · ~3 pages · Grade level 9.7 · Accepted 2025-08-19 06:49:43
Key Financial Figures
- $0.0001 — registered Ordinary shares, par value $0.0001 per share MDT New York Stock Exchange
Filing Documents
- mdt-20250818.htm (8-K) — 67KB
- exhibit991-fy26q1earningsr.htm (EX-99.1) — 504KB
- exhibit992-pressrelease819.htm (EX-99.2) — 17KB
- image_01a.jpg (GRAPHIC) — 25KB
- image_0a.jpg (GRAPHIC) — 25KB
- 0001613103-25-000141.txt ( ) — 970KB
- mdt-20250818.xsd (EX-101.SCH) — 6KB
- mdt-20250818_def.xml (EX-101.DEF) — 24KB
- mdt-20250818_lab.xml (EX-101.LAB) — 50KB
- mdt-20250818_pre.xml (EX-101.PRE) — 26KB
- mdt-20250818_htm.xml (XML) — 17KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition On August 19, 2025, Medtronic plc, a public limited company organized under the laws of Ireland, issued a press release announcing its first quarter fiscal year 2026 financial results. A copy of the press release is furnished as Exhibit 99.1 to this report. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On August 18, 2025, the Board of Directors (Board) of Medtronic plc (Company) increased the size of the Board from 11 to 13 and appointed John Groetelaars and William Jellison as new directors of the Company, in each case, effective as of August 19, 2025. Mr. Jellison has been appointed to serve on the newly created Growth committee of the Board and the newly created Operations committee of the Board, and Mr. Groetelaars has been appointed to serve on the newly created Growth committee of the Board. In connection with the appointment of Messrs. Groetelaars and Jellison to the Board, pursuant to the Company's non-employee director compensation policy, Messrs. Groetelaars and Jellison will each be eligible to receive an annual cash retainer and a director equity grant, in each case as described under "Corporate Governance—Director Compensation" in the Company's Preliminary Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on August 5, 2025. There were no arrangements or understandings between either Mr. Groetelaars and any other persons pursuant to which he was selected as a director, and neither Mr. Groetelaars nor any of his immediate family has been a party to any transaction or currently proposed transaction with the Company that is reportable under Item 404(a) of Regulation S-K. Similarly, there were no arrangements or understandings between Mr. Jellison and any other persons pursuant to which he was selected as a director, and neither Mr. Jellison nor any of
01. Exhibits
Item 9.01. Exhibits. (d) List of Exhibits Exhibit Number Description 99.1 First quarter and fiscal year 2026 earnings press release of Medtronic plc, dated August 19, 2025 99.2 Press release of Medtronic plc, dated August 19, 2025 104 Cover Page Interactive Data File (embedded with the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Medtronic plc By /s/ Thierry Piton Date: August 19, 2025 Thierry Piton Executive Vice President and Chief Financial Officer (Principal Financial Officer) EXHIBIT INDEX Exhibit Number Description 99.1 First quarter and fiscal year 2026 earnings press release of Medtronic plc, dated August 19, 2025 99.2 Press release of Medtronic plc, dated August 19, 2025 104 Cover Page Interactive Data File (embedded with the Inline XBRL document).